Egetis Therapeutics (Q4 review): US approval on the horizon - Redeye

Redeye provides a research update following Egetis' Q4 report and recent events. The rolling NDA submission in the US is complete - and if priority review is granted, the expected decision date (PDUFA) should be in september. We make a few adjustments in our model. 2026 is set to be a transformational year for the company and we review the latest information around the launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1155551/egetis-therapeutics-q4-review-us-approval-on-the-horizon?utm_source=finwire&utm_medium=RSS